Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126506941 | 12650694 | 1 | I | 20160808 | 20160815 | 20160815 | EXP | FR-ROCHE-1810175 | ROCHE | SIGAUX J, HAMZE M, DAIEN C, MOREL J, KRZYSIEK R, PALLARDY M, MAILLERE B AND MARIETTE X. IMMUNOGENICITY OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS. JOINT BONE SPINE 2016;:-. | 0.00 | Y | 0.00000 | 20160815 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126506941 | 12650694 | 1 | PS | Tocilizumab | TOCILIZUMAB | 1 | Unknown | 125276 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126506941 | 12650694 | 1 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126506941 | 12650694 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126506941 | 12650694 | Drug ineffective | |
| 126506941 | 12650694 | Drug specific antibody present | |
| 126506941 | 12650694 | Gastrointestinal perforation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |